Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723444 | 0.88 | ACACB (0.40) | P2RY12ACACBCYP2C9CYP2C19MEN1 | |
| SCHEMBL1012529 | 0.85 | ATM (0.44) | P2RY12MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL1010754 | 0.81 | PCSK9 (0.38) | P2RY12ACACBCYP2C9CYP2C19MEN1 | |
| Trifluoroacetic Acid SCHEMBL1010045 | 0.77 | S1PR1 (0.36) | P2RY12CYP2C9CYP2C19ALDH1A1HRH3 | |
| SCHEMBL16048538 | 0.76 | HDAC3 (0.49) | CYP2C9CYP2C19RAB9A | |
| SCHEMBL28456949 | 0.74 | P2RY12 (0.40) | P2RY12 | |
| SCHEMBL1011264 | 0.74 | NR1D1 (0.46) | P2RY12ALDH1A1GAA | |
| SCHEMBL8250705 | 0.74 | HDAC3 (0.50) | P2RY12CYP2C19ALDH1A1GAAKMT2A | |
| SCHEMBL8251602 | 0.73 | P2RY12 (0.42) | P2RY12ACACBCYP2C19MEN1ALDH1A1 | |
| SCHEMBL17832703 | 0.72 | NOS2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | P2RY12 4870/4885ACACB 1153/4885CYP2C9 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.